Company research / ALZN

Alzamend Neuro, Inc. (ALZN)

Build a valuation ↗↓ Download CSV

CIK 0001677077

Key ratios (year ended 2026-04-30)

-1196.4%

Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 4 · 2026-08-31

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.

Period ended	2026-04-30	2026-01-31	2025-04-30	2024-04-30	2023-04-30	2022-04-30	2021-04-30	2020-04-30	2019-04-30
Operating Income	-$8.77M	—	-$4.50M	-$9.94M	-$14.87M	-$12.32M	-$4.95M	-$4.42M	—
Net Income	-$8.77M	—	-$4.51M	-$9.95M	-$14.88M	-$12.36M	-$5.05M	-$4.41M	—
EPS (Diluted)	$-2.63	—	$-11.32	$-132.33	$-22.89	$-0.14	—	—	—
Total Assets	$2.08M	—	$4.60M	$631.6K	$5.92M	$14.52M	$2.91M	$1.81M	—
Total Liabilities	$1.35M	—	$634.8K	$3.23M	$2.87M	$1.16M	$899.6K	—	—
Shareholders' Equity	$733.2K	$2.20M	$3.97M	-$2.59M	$3.05M	$13.35M	$2.01M	$821.7K	$316.9K
Cash & Equivalents	$710.7K	—	$3.95M	$376.0K	$5.14M	$14.06M	$1.93M	$90.3K	$42.6K
Operating Cash Flow	-$8.07M	—	-$6.57M	-$8.27M	-$8.92M	-$6.61M	-$2.71M	-$2.35M	—
Shares Outstanding	4.26M	—	778.7K	76.4K	646.3K	95.48M	67.43M	64.76M	—
Weighted Average Diluted Shares	3.34M	—	450.8K	74.2K	650.1K	89.10M	—	—	—
EPS (Basic)	$-2.63	—	$-11.32	$-132.33	$-22.89	$-0.14	—	—	—